From Nasdaq: 2025-05-22 22:10:00

The US FDA has approved GSK plc.’s Nucala as a maintenance treatment for COPD in adult patients with an eosinophilic phenotype. Data from phase III trials showed a significant reduction in exacerbations compared to placebo. Mepolizumab is not approved for COPD in other countries, with regulatory submissions under review in China and Europe. For more health news, visit rttnews.com. (Source: RTTNews)



Read more at Nasdaq: GSK : FDA Approves Nucala As Add-on Maintenance Treatment For Chronic Obstructive Pulmonary Disease